Getting an accurate allergy diagnosis is empowering. At HYCOR, we believe that people with an allergy improve their quality of life when they know exactly what is causing their symptoms.
NOVEOS is the first breakthrough technology for routine allergy testing in 20 years. It combines proven technologies with innovative methodologies that deliver higher quality results and reduce operational costs through improved efficiency.
NOVEOS was developed using extensive input from labs and clinicians around the world and with the knowledge of the shortcomings of existing technologies within allergy testing.
NOVEOS, designed with your lab in mind HYCOR proudly presents the NOVEOS system, the NEW STANDARD in allergy testing solving shortcomings of current technologies. NOVEOS is ideal for mid to high volume laboratories that routinely test for specific IgE. It requires only 4-μL sample size per test, reduces lack-of-sample errors, resampling, and patient trauma.
The advanced micro-particle technology limits interference from: Biotin, IgG / IgG4, and Solid-phase related cross-reactive carbohydrate determinant (CCD) binding.
NOVEOS offers high sensitivity, excellent low-end precision, and operates for up to 13 hours of true walk-away capability. The NOVEOS system utilizes microparticles that are approximately 1µm in size, each smaller than the diameter of a human hair.
Sample requirements: NOVEOS system can run 10x more tests with the same sample current system use
- The 4 μL sample size is a breakthrough
- Allergy profile typically has 1-35 tests per patient
- NOVEOS instrument uses 40-50 µL of sample per specific IgE test
- Reflex component allergen testing will exacerbate sample shortages
- Reduce the potential loss of revenue for the laboratory
NOVEOS Microparticle TECHNOLOGY The assay design, small sample size, and vast surface area of paramagnetic microparticles provide superior capacity to minimize interference and non-specific binding.
Each test contains more than 35 million high-capacity paramagnetic microparticles (Fluo Bead™), providing a vast surface area, high binding capacity, and allowing the use of a 4 µL sample volume. This leads to excellent performance and accurate results.
- Patented dual signal for excellent performance and accurate results
- Minimal QNS and interfering material
- Proven ultrasensitive detection
Interference Avoidance NOVEO is the new standard to limit the impact of interferences! Getting the right answers matters to make reliable clinical decisions. Assays are designed to limit interference from Biotin, IgG/IgG4, or solid-phase related cross-reactive carbohydrate determinants (CCD).
- Avoiding False Negatives: The NOVEOS indirect assay design avoids competition for binding sites by patient allergen-specific antibodies and endogenous biotin in a patient sample.
- Avoiding False Positives: The NOVEOS assay is unaffected by biotin or cellulose-based CCD interference.
- Small sample volume per test leads to less interference from serum-based substances.
- Microparticle approach gives a dramatic increase in surface area leading to superb sensitivity.
- No solid-phase related CCD Interference with NOVEOS IgE paramagnetic microparticles.
NOVEOS automation
- Allows the use of a 4 µL sample volume
- Reduced hands-on time and overhead means
- High on-board test capacity of 10,500 tests
- Avoiding Quantity Not Sufficient (QNS) occurrences
- Microparticle allergy testing with high binding capacity
- 60 sample positions
- 100 tests per hour
- High sensitivity and excellent low-end precision
- Accurate & precise results
- Assays designed to limit interference from Biotin, IgG/IgG4, or solid-phase related CCD
Our NOVEOS Analyzers
Getting an accurate allergy diagnosis is empowering. At HYCOR, we believe that people with an allergy improve their quality of life when they know exactly what is causing their symptoms.
NOVEOS is the first breakthrough technology for routine allergy testing in 20 years. It combines proven technologies with innovative methodologies that deliver higher quality results and reduce operational costs through improved efficiency.
NOVEOS was developed using extensive input from labs and clinicians around the world and with the knowledge of the shortcomings of existing technologies within allergy testing.
NOVEOS, designed with your lab in mind HYCOR proudly presents the NOVEOS system, the NEW STANDARD in allergy testing solving shortcomings of current technologies. NOVEOS is ideal for mid to high volume laboratories that routinely test for specific IgE. It requires only 4-μL sample size per test, reduces lack-of-sample errors, resampling, and patient trauma.
The advanced micro-particle technology limits interference from: Biotin, IgG / IgG4, and Solid-phase related cross-reactive carbohydrate determinant (CCD) binding.
NOVEOS offers high sensitivity, excellent low-end precision, and operates for up to 13 hours of true walk-away capability. The NOVEOS system utilizes microparticles that are approximately 1µm in size, each smaller than the diameter of a human hair.
Sample requirements: NOVEOS system can run 10x more tests with the same sample current system use
- The 4 μL sample size is a breakthrough
- Allergy profile typically has 1-35 tests per patient
- NOVEOS instrument uses 40-50 µL of sample per specific IgE test
- Reflex component allergen testing will exacerbate sample shortages
- Reduce the potential loss of revenue for the laboratory
NOVEOS Microparticle TECHNOLOGY The assay design, small sample size, and vast surface area of paramagnetic microparticles provide superior capacity to minimize interference and non-specific binding.
Each test contains more than 35 million high-capacity paramagnetic microparticles (Fluo Bead™), providing a vast surface area, high binding capacity, and allowing the use of a 4 µL sample volume. This leads to excellent performance and accurate results.
- Patented dual signal for excellent performance and accurate results
- Minimal QNS and interfering material
- Proven ultrasensitive detection
Interference Avoidance NOVEO is the new standard to limit the impact of interferences! Getting the right answers matters to make reliable clinical decisions. Assays are designed to limit interference from Biotin, IgG/IgG4, or solid-phase related cross-reactive carbohydrate determinants (CCD).
- Avoiding False Negatives: The NOVEOS indirect assay design avoids competition for binding sites by patient allergen-specific antibodies and endogenous biotin in a patient sample.
- Avoiding False Positives: The NOVEOS assay is unaffected by biotin or cellulose-based CCD interference.
- Small sample volume per test leads to less interference from serum-based substances.
- Microparticle approach gives a dramatic increase in surface area leading to superb sensitivity.
- No solid-phase related CCD Interference with NOVEOS IgE paramagnetic microparticles.
NOVEOS automation
- Allows the use of a 4 µL sample volume
- Reduced hands-on time and overhead means
- High on-board test capacity of 10,500 tests
- Avoiding Quantity Not Sufficient (QNS) occurrences
- Microparticle allergy testing with high binding capacity
- 60 sample positions
- 100 tests per hour
- High sensitivity and excellent low-end precision
- Accurate & precise results
- Assays designed to limit interference from Biotin, IgG/IgG4, or solid-phase related CCD
Our NOVEOS Analyzers
